Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Cited by (1,009)

Items 601–700 of 1,009

1. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein
   Christine Rebischung, Raphaelle Barnoud, Laëtitia Stefani, Jean‐Luc Faucheron, Mireille Mousseau · 2005 · Gastric Cancer
2. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
   Carlos L. Arteaga · 2003 · Breast Cancer Research
3. Assessing Patient Readiness for the Clinical Adoption of Personalized Medicine
   Issa, A.M., Tufail, W., Hutchinson, J., Tenorio, J., Baliga, M. Poonam · 2009 · Public Health Genomics
4. Near‐Infrared Light and pH Dual‐Responsive Targeted Drug Carrier Based on Core‐Crosslinked Polyaniline Nanoparticles for Intracellular Delivery of Cisplatin
   Chaoqun You, Hongshuai Wu, Minxing Wang, Yawen Zhang, Jingwen Wang, Yanghui Luo, Lihai Zhai, Bai‐Wang Sun, Xiangyang Zhang, Jin Zhu · 2017 · Chemistry - A European Journal
5. Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer
   Sucheta Kulkarni, Kumar B. Reddy, Francisco J. Esteva, H C F Moore, George Thomas Budd, Raymond R. Tubbs · 2009 · Oncogene
6. Chromogenic In Situ Hybridization to Detect HER-2/neu Gene Amplification in Histological and ThinPrep®-Processed Breast Cancer Fine-Needle Aspirates: A Sensitive and Practical Method in the Trastuzumab Era
   Amina Vocaturo, Flavia Novelli, Maria Benevolo, Giulia Piperno, Ferdinando Marandino, Anna Maria Cianciulli, Roberta Merola, Raffaele Perrone Donnorso, Isabella Sperduti, Simonetta Buglioni et al. · 2006 · The Oncologist
7. Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
   Daniel Wetterskog, K-K. Shiu, Irene Yu-Shing Chong, Titia G. Meijer, Alan G. Mackay, Maryou B.K. Lambros, David Cunningham, Jorge Sergio Reis-Filho, Christopher J. Lord, Alan Ashworth · 2013 · Oncogene
8. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment
   Chunhua Xiao, Yun Yun Gong, Eric Han, Ana Maria Gonzalez-Angulo, Nour Sneige · 2011 · Annals of Oncology
9. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin‐fixed breast carcinoma cell block preparations: Correlation of results to corresponding tissue block (needle core and excision) samples
   Mary D. Kinsella, George G. Birdsong, Momin T. Siddiqui, Cynthia Cohen, Krisztina Z. Hanley · 2012 · Diagnostic Cytopathology
10. FOXO1A Is a Target for HER2-Overexpressing Breast Tumors
    Yanyuan Wu, Xiying Shang, Marianna Sarkissyan, Dennis J. Slamon, Jaydutt V. Vadgama · 2010 · Cancer Research
11. HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
    Rafał Zieliński, Ilya G. Lyakhov, Moinuddin Hassan, Monika Kuban, Kimberly Shafer-Weaver, Amir Gandjbakhche, Jacek Capala · 2011 · Clinical Cancer Research
12. Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
    Celia Nieto, Milena A. Vega, Eva M. Martín del Valle · 2020 · Nanomaterials
13. Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies
    Christian Fridolin Singer, Wolfgang J. Köstler, Gernot Hudelist · 2008 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
14. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies
    Alessandra Fabi, Giulio Metro, Gianluigi Ferretti, Diana Giannarelli, Serena Di Cosimo, Paola Papaldo, Marcella Mottolese, Paolo Carlini, Alessandra Felici, Michelangelo Russillo et al. · 2008 · The Breast
15. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
    Ahmad Hussein Awada, Joan Albanell, Peter A. Canney, Luc Yves Dirix, Thierry Gil, Fátima Cardoso, Pere Gascón, Martine J Piccart, Jose M Baselga · 2008 · British Journal of Cancer
16. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: An unexpected effect on TRAIL‐induced apoptosis
    Lenka Zdražilová Dubská, Ladislav Anděra, Michael Allen Sheard · 2005 · FEBS Letters
17. Her‐2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab‐based therapy in patients with metastatic breast cancer
    Gernot Hudelist, Wolfgang J. Köstler, Klaus F Czerwenka, Ernst Kubista, Johannes Attems, Ruth Müller, Daphne Gschwantler‐Kaulich, Mahmood Manavi, Isabell Huber, Heinz Hoschützky et al. · 2005 · International Journal of Cancer
18. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
    Yanyuan Wu, Hezla Mohamed, Ram K. Chillar, Ishrat Ali, Sheila Clayton, Dennis J. Slamon, Jaydutt V. Vadgama · 2008 · Breast Cancer Research
19. The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma
    Melike Pekmezci, Anna M. Szpaderska, Clodia Osipo, Çağatay H. Erşahin · 2012 · Pathology Research International
20. Quantitative Analysis of Surface Plasma Membrane Proteins of Primary and Metastatic Melanoma Cells
    Haibo Qiu, Yinsheng Wang · 2008 · Journal of Proteome Research
21. Multiformat T‐Cell‐Engaging Bispecific Antibodies Targeting Human Breast Cancers
    Yu J Cao, Jun Y. Axup, Jennifer S. Y. Ma, Rongsheng E. Wang, Seihyun Choi, Virginie Tardif, Reyna K. V. Lim, Holly M. Pugh, Brian R. Lawson, Gus Welzel et al. · 2015 · Angewandte Chemie International Edition
22. Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications
    Jamunarani Veeraraghavan, Jiacheng Ma, Yiheng Hu, Xiao-Song Wang · 2016 · Breast Cancer Research and Treatment
23. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells
    Jaspreet Dhillon, Arezoo Astanehe, C Lee, Abbas Fotovati, Kaiji Hu, Sandra Elaine Dunn · 2010 · Oncogene
24. Solamargine Enhances HER2 Expression and Increases the Susceptibility of Human Lung Cancer H661 and H69 Cells to Trastuzumab and Epirubicin
    Chia‐Hua Liang, Li‐Yen Shiu, Li-Ching Chang, Hamm‐Ming Sheu, Eing‐Mei Tsai, Kou‐Wha Kuo · 2007 · Chemical Research in Toxicology
25. Systemic cancer therapy: Evolution over the last 60 years
    Grace Kho Dy, Alex A. Adjei · 2008 · Cancer
26. Theranostic and Molecular Classification of Breast Cancer
    Kristine M. Cornejo, Dina H. Kandil, Ashraf Ali Khan, Ediz F. Cosar · 2013 · Archives of Pathology & Laboratory Medicine
27. Human Epidermal Growth Factor Receptor 2–Targeting [ 68 Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer
    Ali Alhuseinalkhudhur, Henrik Lindman, Per Liss, Tora Sundin, Fredrik Y. Frejd, Johan Hartman, Victor Vishwanath Iyer, Joachim Feldwisch, Mark Lubberink, Caroline Rönnlund et al. · 2023 · Journal of Nuclear Medicine
28. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
    Silvia Boero, Anna Morabito, Barbara Banelli, Bárbara Cardinali, Béatrice Dozin, Gianluigi Lunardi, Patrizia Piccioli, Sonia Lastraioli, Roberta Carosio, Sandra Salvi et al. · 2015 · Journal of Translational Medicine
29. A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy
    Marc Turini, Patrick Chames, Pierre Bruhns, Daniel Baty, Brigitte Kerfélec · 2014 · Oncotarget
30. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF‐1 receptor tyrosine kinases, blocks the growth of HER2‐overexpressing human breast cancer cells
    Marianna Zavodovskaya, Michael J. Campbell, Betty A. Maddux, Laura Shiry, Geoffrey Allan, Leslie Hodges-Gallagher, Peter J. Kushner, John A. Kerner, JACK F. YOUNGREN, Ira D. Goldfine · 2007 · Journal of Cellular Biochemistry
31. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation
    Marco P. Licciardello, Markus K. Müllner, Gerhard Dürnberger, Claudia Kerzendorfer, Bernd Boidol, Claudia Jessen‐Trefzer, Sara Sdelci, Tobias Berg, Thomas Penz, Michael K. Schuster et al. · 2014 · Oncogene
32. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer
    Wolfgang J. Köstler, Gernot Hudelist, Werner Rabitsch, Klaus F Czerwenka, Ruth Müller, Christian Fridolin Singer, Christoph Carl Zielinski · 2005 · Journal of Cancer Research and Clinical Oncology
33. Lapatinib: A Sword With Two Edges
    László Kopper · 2008 · Pathology & Oncology Research
34. Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen
    Anthony H. Kong, Daniel William Rea, Samreen I. Ahmed, Joseph Thaddeus Beck, Rafael López‐López, Laura Biganzoli, Anne Caroline Armstrong, Massimo Aglietta, Emilio Alba, Mario Campone et al. · 2016 · Oncotarget
35. HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology
    Etienne G.C. Brain, Philippe Caillet, Nienke A. de Glas, Laura Biganzoli, Karis Kin Fong Cheng, Lissandra Dal Lago, Hans P. M. W. Wildiers · 2019 · Journal of Geriatric Oncology
36. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
    Xuesai Zhang, Jianhe Chen, Zhibing Weng, Qingrou Li, Le Zhao, Ning Yu, Lan Deng, Wei Xu, Yan Yang, Zhenping Zhu et al. · 2020 · Molecular Immunology
37. Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro
    Stephan N. Wagner, Christine Häfner, Dorothee Allwardt, Joanna Jasińska, Soldano Ferrone, Christoph Carl Zielinski, Otto Scheiner, Ursula Wiedermann, Hubert Pehamberger, Heimo Breiteneder · 2005 · The Journal of Immunology
38. Comparison of HER 2 expression between primary colorectal cancer and their corresponding metastases
    Won‐Suk Lee, Yeon Ho Park, Jung Nam Lee, Jeong‐Heum Baek, Tae‐Hoon Lee, Seung Yeon Ha · 2014 · Cancer Medicine
39. Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2 Gene–Amplified Breast Cancer Cells
    Michèle Milella, Daniela Trisciuoglio, Tiziana Bruno, Ludovica Ciuffreda, Marcella Mottolese, Anna Maria Cianciulli, Francesco Cognetti, Uwe Zangemeister‐Wittke, Donatella Del Bufalo, Gabriella Zupi · 2004 · Clinical Cancer Research
40. Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology
    Michelino De Laurentiis, Giuseppe Cancello, Luigia Zinno, Emilia Montagna, Luca Malorni, A. Esposito, Roberta Maria Pennacchio, Lucrezia Silvestro, Mario Giuliano, Antonio Giordano et al. · 2005 · Annals of Oncology
41. The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
    Johann Sebastian De Bono, Anthony W. Tolcher, Eric Keith Rowinsky · 2003 · Breast Cancer Research
42. Taxanes in breast cancer: An update
    Alison Katherine Conlin, Andrew David Seidman · 2007 · Current Oncology Reports
43. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Hope S. Rugo, Amy Jo Chien, Sandra X. Franco, Alison Stopeck, Alexa Glencer, Soumi Lahiri, Michael C. Arbushites, Janet H. Scott, John W. Park, Clifford A. Hudis et al. · 2011 · Breast Cancer Research and Treatment
44. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer
    Jacob Mathew, Edith A. Perez · 2011 · Current Opinion in Oncology
45. Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics
    Orit Jacobson, Xiaoyuan Shawn Chen · 2013 · Pharmacological Reviews
46. Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer
    Danica L. Rowe, Tuba Ozbay, Laura M. Bender, Rita Nahta · 2008 · Molecular Cancer Therapeutics
47. Targeting chromosomal instability and tumour heterogeneity in HER2‐positive breast cancer
    Rebecca A. Burrell, Nicolai J. Birkbak, Stephen R.D. Johnston, Jorge Sergio Reis-Filho, Zoltán Szállási, Charles Swanton · 2010 · Journal of Cellular Biochemistry
48. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer
    Lichao Sun, Joseph Burnett, Mari Gasparyan, Fangying Xu, Hui Jiang, Chang-Ching A. Lin, Ila Myers, Hasan Körkaya, Yajing Liu, Jamie N. Connarn et al. · 2016 · Oncotarget
49. Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer
    Francesca Ligorio, Ilaria Pellegrini, Lorenzo Castagnoli, Andrea Vingiani, Riccardo Lobefaro, Emma Zattarin, Marzia Santamaria, Serenella Maria Pupa, Giancarlo Pruneri, Filippo de Braud et al. · 2021 · Cancer Letters
50. High-level amplification at 17q23 leads to coordinated overexpression of multiple adjacent genes in breast cancer
    Jenita Pärssinen, Tuula Kuukasjärvi, Ritva Karhu, Anne H. Kallioniemi · 2007 · British Journal of Cancer
51. HER-2/neu and Topoisomerase IIα Gene Amplification and Protein Expression in Invasive Breast Carcinomas
    Rohit Bhargava, Priti Lal, Beiyun Chen · 2005 · American Journal of Clinical Pathology
52. Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma
    Santiago Ropero, Javier Abel Menéndez, Alejandro Vázquez‐Martín, Sagrario Montero, H. Cortés-Funes, Rámón Colomer · 2004 · Breast Cancer Research and Treatment
53. Clinical Genome Sequencing
    R. Green, H. Rehm, I. Kohane · 2013 · Elsevier eBooks
54. IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance
    Colin D. White, Zhigang Li, Deborah A. R. Dillon, David B. Sacks · 2011 · Journal of Biological Chemistry
55. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance
    Xiaoping Huang, Shuiliang Wang, Choon‐Kee Lee, Xiaohe Yang, Bolin Liu · 2011 · Cancer Letters
56. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity
    Gauri Akolkar, Navdeep Bhullar, Hilary J. Bews, Bilal Shaikh, Sheena Premecz, Kimberly-Ann Bordun, David Y. C. Cheung, Vineet Goyal, Anita K. Sharma, Philip J. Garber et al. · 2015 · Cardiovascular Ultrasound
57. Two‐Step Targeted Hybrid Nanoconstructs Increase Brain Penetration and Efficacy of the Therapeutic Antibody Trastuzumab against Brain Metastasis of HER2‐Positive Breast Cancer
    Chunsheng He, Jason Li, Ping Cai, Taksim Ahmed, Jeffrey Theodore Henderson, Warren D. Foltz, Reina Bendayan, Andrew Michael Rauth, Xiao Yu Wu · 2018 · Advanced Functional Materials
58. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars
    Megan Elizabeth Tesch, Karen A. Gelmon · 2020 · Drugs
59. HER-2 (c-erbB-2) test update: Present status and problems
    Hitoshi Tsuda · 2006 · Breast Cancer
60. Therapeutic Targeting of DNA Replication Stress in Cancer
    Long Gu, Robert J. Hickey, Linda H. Malkas · 2023 · Genes
61. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein
    Hyun-Mi Cho, Joseph D. Rosenblatt, Young‐Sook Kang, M. Luisa Iruela‐Arispe, Sherie Leaver Morrison, Manuel L. Penichet, Young‐Guen Kwon, Tae‐Woong Kim, Keith A. Webster, Hovav Nechushtan et al. · 2005 · Molecular Cancer Therapeutics
62. HER2 Silences Tumor Suppression in Breast Cancer Cells by Switching Expression of C/EBPβ Isoforms
    Anna Arnal Estape, Maria Tarragona, M.L González Morales, Marc Guiu, Cristina Nadal, Joan Massagué, Roger R. Gomis · 2010 · Cancer Research
63. Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer
    Somaira Nowsheen, Paul Vincent Viscuse, Ciara Catherine O'Sullivan, Nicole P. Sandhu, Tufia C. Haddad, Anne Hudson Blaes, Jennifer R. Klemp, Lara Ferreira Nhola, Joerg Herrmann, Kathryn J. Ruddy · 2017 · Current Breast Cancer Reports
64. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy
    Yanjun Hou, Hiroaki Nitta, Lai Wei, Peter M. Banks, Anil Vasdev Parwani, Zaibo Li · 2017 · Clinical Breast Cancer
65. Mammary Development and Breast Cancer: a Notch Perspective
    Weizhen Chen, Wei Wei, Liya Yu, Zi Ye, Fujing Huang, Liyan Zhang, Shiqi Hu, Cheguo Cai · 2021 · Journal of Mammary Gland Biology and Neoplasia
66. Metastatic Breast Cancer
    S.M. Ali, Harold A. Harvey, Allan Lipton · 2003 · Clinical Orthopaedics and Related Research
67. Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary Carcinomas
    Agostinho Pinto Gouvêa, Fernanda Milanezi, Sandra Jean Olson, Dina Leitão, Fernando Carlos Schmitt, Helenice Gobbi · 2005 · Applied immunohistochemistry & molecular morphology
68. 213Bi (α-Emitter)–Antibody Targeting of Breast Cancer Metastases in theneu-N Transgenic Mouse Model
    Song Hong, Karineh Shahverdi, David L. Huso, Caroline E. Esaias, James M. Fox, Allison Liedy, Zhe Zhang, R. Todd Reilly, Christos Apostolidis, Alfred Morgenstern et al. · 2008 · Cancer Research
69. The Medical Management of Pancreatic Cancer: A Review
    Sarah McKenna, Martin McKinlay Eatock · 2003 · The Oncologist
70. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
    Andrew R. Green, F. Barros, Tarek Mohamed Ahmed Abdel-Fatah, Paul M. Moseley, Christopher C. Nolan, Alice C. Durham, Emad A. Rakha, Stephen Y.T. Chan, Ian Ogilvie Ellis · 2014 · Breast Cancer Research and Treatment
71. Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity
    Peng Guo, Jin‐Oh You, Jiang Yang, Marsha A. Moses, Debra T. Auguste · 2012 · Biomaterials
72. In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts
    Devin R. McCormack, Alex J. Walsh, Wesley W. Sit, Carlos L. Arteaga, Jin Chen, Rebecca S. Cook, Melissa C. Skala · 2014 · Biomedical Optics Express
73. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy
    Nicholas B. Figura, Victoria T. Rizk, Homan Mohammadi, Brittany R. Evernden, Sepideh Mokhtari, Yu Hc, Timothy J. Robinson, Arnold B. Etame, Nam Tran, James K. Liu et al. · 2019 · Breast Cancer Research and Treatment
74. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
    Janusz Mezynski, Angela M. Farrelly, Mattia Cremona, Aoife Carr, Clare Morgan, Julie A. Workman, Paul Armstrong, Jennifer McAuley, Stephen F. Madden, Joanna Fay et al. · 2021 · Journal of Translational Medicine
75. Laboratory Compliance With the American Society of Clinical Oncology/College of American Pathologists Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: A College of American Pathologists Survey of 757 Laboratories
    Raouf E. Nakhleh, Erin E. Grimm, Michael O. Idowu, Rhona J. Souers, Patrick L. Fitzgibbons · 2010 · Archives of Pathology & Laboratory Medicine
76. PC Cell–Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells
    Wes E. Kim, Ginette Serrero · 2006 · Clinical Cancer Research
77. Multifunctional receptor-targeting antibodies for cancer therapy
    Yanni Zhu, Sung Hugh Choi, Khalid Shah · 2015 · The Lancet Oncology
78. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results
    Anna G. Sorace, C. Chad Quarles, Jennifer G. Whisenant, Ariella B. Hanker, J. Oliver McIntyre, Violeta M. Sanchez, Thomas E. Yankeelov · 2016 · Breast Cancer Research and Treatment
79. Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
    Johannes Laengle, Julijan Kabiljo, Leah Hunter, Jakob Homola, Sophie Prodinger, Gerda Egger, Michael M. Bergmann · 2020 · Journal for ImmunoTherapy of Cancer
80. Advancement in research and therapy of NF1 mutant malignant tumors
    Junyan Tao, Dantong Sun, Lina Dong, Hua Zhu, Helei Hou · 2020 · Cancer Cell International
81. A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease
    Andrew M. Erickson, Alicia Hayes, Timothy Rajakumar, Clare L. Verrill, Richard J. Bryant, Freddie Charles Hamdy, David C. Wedge, Dan J. Woodcock, Ian Geoffrey Mills, Alastair D.G. Lamb · 2021 · European Urology Oncology
82. Expression of HER2 and C-KIT in Nasopharyngeal Carcinoma: Implications for a New Therapeutic Approach
    Gil Bar‐Sela, Abraham Kuten, Shoshana Ben-Eliezer, Eliav Gov‐Ari, Ofer Ben‐Izhak · 2003 · Modern Pathology
83. Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
    Inderjit K. Dev, Ronna E. Dornsife, Teresa M. Hopper, James A. Onori, Charles G. Miller, L E Harrington, Karen M. Dold, Robert J. Mullin, Jennifer H. Johnson, Renae M. Crosby et al. · 2004 · British Journal of Cancer
84. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
    Cecilia Bozzetti, Nicola Personeni, Rita Nizzoli, Annamaria Guazzi, Marcella Flora, Cristina Bassano, Francesca Negri, Eugenia Marta Martella, Nadia Naldi, Vittorio Franciosi et al. · 2003 · Cancer
85. ERBB1 and ERBB2 Have Distinct Functions in Tumor Cell Invasion and Intravasation
    Dmitriy Kedrin, Jeffrey B. Wyckoff, Pamela J. Boimel, Salvatore J. Coniglio, Nancy E. Hynes, Carlos L. Arteaga, Jeffrey E. Segall · 2009 · Clinical Cancer Research
86. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells
    Michele L. Scotti, John Fairbanks Langenheim, Seth Tomblyn, Alison E. B. Springs, Wen Y. Chen · 2007 · Breast Cancer Research and Treatment
87. Interlaboratory Comparison of Immunohistochemical Testing for HER2: Results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey
    Patrick L. Fitzgibbons, Douglas A. Murphy, David M. Dorfman, Patrick C. Roche, Raymond R. Tubbs · 2006 · Archives of Pathology & Laboratory Medicine
88. Pharmacogenetics—expectations and reality
    Geoff T. Tucker · 2004 · BMJ
89. Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network
    Annabel Borley, T Mercer, M Morgan, P Dutton, Peter J. Barrett-Lee, Matteo Brunelli, Bharat Jasani · 2014 · British Journal of Cancer
90. Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists
    Antonino Carbone, Gerardo Botti, Annunziata Gloghini, Gianni Simone, Mauro Truini, Maria Pia Curcio, Patrizia Gasparini, Anita Mangia, Tiziana Perin, Sandra Salvi et al. · 2008 · Journal of Molecular Diagnostics
91. The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics
    Jessica M. Scott, Susan C. Gilchrist, John Robert Mackey, Pamela S. Douglas, Mark J. Haykowsky, Lee W. Jones · 2013 · The Oncologist
92. An Elective Course to Engage Pharmacy Students in Research Activities
    Victoria E. Palau · 2011 · American Journal of Pharmaceutical Education
93. Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy
    Vishal Kothari, Iris H. Wei, Sunita Shankar, Shanker Kalyana Sundaram, Lidong Wang, Linda W. Ma, Pankaj Vats, Catherine S. Grasso, Dan R. Robinson, Yi-Mi Wu et al. · 2013 · Cancer Discovery
94. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study
    Joaquín Gavilá, Miguel Ángel Seguí, Lourdes Calvo, T. López, Joaquín J. Alonso, M. Farto, Rainel Sánchez-de la Rosa · 2016 · Clinical & Translational Oncology
95. Immunotherapy for Breast Cancer: Current and Future Strategies
    Austin David Williams, Kyle K. Payne, Avery D. Posey, Christine Hill, Jose Ramon Conejo-Garcia, Carl H. June, Julia C. Tchou · 2017 · Current Surgery Reports
96. Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial
    Dhivya R. Sudhan, Luis Jesus Schwarz, Ángel Guerrero Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González Ericsson, Melinda E. Sanders, Justin Micah Balko, Francesca Avogadri-Connors et al. · 2018 · Clinical Cancer Research
97. HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells
    Parul Gupta, Nehal Gupta, Neel Manoj Fofaria, Alok Ranjan, Sanjay Srivastava · 2018 · Cancer Letters
98. Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options
    Alberto Ocaña, Atanasio Pandiella · 2008 · Clinical Cancer Research
99. Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer
    Filippo Montemurro, Aleix Prat, Valentina Rossi, Giorgio Valabrega, Jeff Sperinde, Caterina Peraldo Neia, Michela Donadio, Patricia Galván, Anna Sapino, Massimo Aglietta et al. · 2013 · Molecular Oncology
100. Role of phosphoproteomics in the development of personalized cancer therapies
     Pedro R. Cutillas · 2014 · PROTEOMICS - CLINICAL APPLICATIONS